Market closed

Lyell Immunopharma/$LYEL

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Lyell Immunopharma

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Ticker

$LYEL

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

South San Francisco, United States

Employees

224

Website

lyell.com

LYEL Metrics

BasicAdvanced

$168M

-

-$0.80

-0.48

-

Price and volume

Market cap

$168M

Beta

-0.48

52-week high

$3.26

52-week low

$0.55

Average daily volume

1.2M

Financial strength

Current ratio

13.429

Quick ratio

13.146

Long term debt to equity

9.693

Total debt to equity

11.037

Management effectiveness

Return on assets (TTM)

-19.12%

Return on equity (TTM)

-33.22%

Valuation

Price to revenue (TTM)

2,325.911

Price to book

0.28

Price to tangible book (TTM)

0.28

Price to free cash flow (TTM)

-0.937

Growth

Revenue change (TTM)

-99.87%

Earnings per share change (TTM)

5.39%

3-year revenue growth (CAGR)

-81.62%

3-year earnings per share growth (CAGR)

-32.39%

What the Analysts think about LYEL

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Lyell Immunopharma stock.

LYEL Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

LYEL Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

LYEL News

AllArticlesVideos

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

GlobeNewsWire·6 days ago

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

GlobeNewsWire·1 month ago

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

GlobeNewsWire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $LYEL

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Lyell Immunopharma stock?

Lyell Immunopharma (LYEL) has a market cap of $168M as of January 15, 2025.

What is the P/E ratio for Lyell Immunopharma stock?

The price to earnings (P/E) ratio for Lyell Immunopharma (LYEL) stock is 0 as of January 15, 2025.

Does Lyell Immunopharma stock pay dividends?

No, Lyell Immunopharma (LYEL) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Lyell Immunopharma dividend payment date?

Lyell Immunopharma (LYEL) stock does not pay dividends to its shareholders.

What is the beta indicator for Lyell Immunopharma?

Lyell Immunopharma (LYEL) has a beta rating of -0.48. This means that it has an inverse relation to market volatility.